Emergency FundingLast Reviewed: April 2026CM-INS-091 // APRIL 2026
BARDA Emergency Funding 2026: New Opportunities for Medical Countermeasure Development
BARDA's funding mechanisms are less visible than NIH grants but arguably more consequential for medical countermeasure development — the agency has been the financial engine behind most of the pandemic-era vaccine and therapeutic programs, and its current priorities in 2026 reflect both post-COVID lessons and an expanding threat landscape. For researchers and companies working in infectious disease preparedness, radiological countermeasures, or chemical agent treatment, understanding how BARDA thinks about risk-sharing contracts versus traditional grants matters enormously for how you structure a proposal.
Funding Notice
BARDA funding information is intended for pharmaceutical, biotech, and medical device developers engaged in medical countermeasure research. BARDA contracts and grants are subject to federal acquisition regulations and HHS oversight. Verify current solicitations at sam.gov and barda.hhs.gov.
Summary
BARDA (Biomedical Advanced Research and Development Authority), within HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR), funds the advanced development of medical countermeasures (MCMs) — vaccines, therapeutics, diagnostics, and devices — against CBRN (chemical, biological, radiological, nuclear) threats, pandemic influenza, and emerging infectious diseases. BARDA's annual budget exceeds $3 billion and it uses a range of mechanisms including large OTA (Other Transaction Authority) contracts, traditional R&D contracts, and the DRIVe innovation accelerator for early-stage solutions. BARDA actively solicits new partners through BAAs (Broad Agency Announcements) and industry days throughout 2026.
Emerging infectious disease: Platform technologies applicable to novel pathogens, broad-spectrum antivirals and antibacterials, point-of-care diagnostics for outbreak response
Biological threat countermeasures: Treatments and prophylactics against anthrax, botulinum, smallpox, Ebola, and other Category A-C biological agents listed in the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) strategy
Chemical threat countermeasures: Nerve agent antidotes, skin decontamination solutions, mass casualty management drugs deployable by first responders
Radiological/nuclear countermeasures: Radiation injury treatments, biodosimetry diagnostics, medical management tools for nuclear incident response
Platform manufacturing technologies: Surge manufacturing capacity for vaccines and therapeutics, distributed manufacturing innovations for supply chain resilience
BARDA Funding Mechanisms
OTA (Other Transaction Authority) Contracts: BARDA's most flexible and preferred mechanism for MCM development. Not subject to Federal Acquisition Regulations (FAR) — allows faster contracting, milestone-based payments, and novel partnership structures. Typical OTAs range from $1M to $500M+. BARDA issues BAAs (Broad Agency Announcements) soliciting OTA proposals.
DRIVe (Division of Research, Innovation, and Ventures): BARDA's accelerator for early-stage, innovative MCM solutions. DRIVe offers non-dilutive funding ($250K–$2M), regulatory guidance, and introductions to BARDA product development teams. Focus areas in 2026 include AI-based diagnostics, next-generation manufacturing, and antimicrobial resistance.
Traditional R&D Contracts: FAR-compliant cost-plus or fixed-price contracts for companies with established regulatory and contracting infrastructure. Used for manufacturing scale-up and late-phase clinical development.
BARDA Ventures: Equity investment program for early-stage MCM companies. BARDA Ventures can co-invest alongside private investors, providing both funding and a USG partnership signal to attract additional capital.
How to Engage with BARDA
Step 1 — Monitor BARDA BAAs on SAM.gov: Search SAM.gov for "BARDA" or "ASPR" in the opportunity search. BARDA's primary BAA (currently BAA-18-100-SOL-00003) is an omnibus announcement accepting proposals on a rolling basis across all MCM areas.
Step 2 — Submit a White Paper or Concept Paper: Before a full proposal, BARDA typically requests a 5–10 page White Paper describing the technology, development status (TRL), regulatory strategy, proposed milestones, and funding ask. BARDA provides written feedback within 60 days on whether a full proposal is invited.
Step 3 — Attend BARDA Industry Days: BARDA hosts annual and quarterly Industry Days in Washington, D.C. where program managers present priority areas and companies can schedule brief one-on-one meetings. These meetings are critical for understanding specific program needs and establishing relationships with technical staff.
Step 4 — Apply to DRIVe for early-stage companies: If your technology is TRL 1–4, DRIVe offers a faster path to BARDA engagement than the main BAA. Submit a brief application through the DRIVe portal at medicalcountermeasures.gov/drive.
Step 5 — Prepare for due diligence: BARDA conducts extensive technical, regulatory, and financial due diligence before awarding contracts. Companies should have a clear regulatory development plan, Phase II/III clinical data or plan, manufacturing scale-up strategy, and awareness of SNS (Strategic National Stockpile) procurement requirements.
Clinical Trial Research & Intelligence · Est. 2025
This article was researched and written by the ClinicalMetric editorial team using primary sources: ClinicalTrials.gov registry data (NIH/NLM), FDA trial documentation, peer-reviewed literature from PubMed/MEDLINE, and EudraCT (EU Clinical Trials Register). Trial status, eligibility criteria, and enrollment data are sourced directly from official registry APIs — not secondary aggregators.
📅 Last reviewed: 2026-04-02🔄 Trial data updated daily from ClinicalTrials.gov
◆ Editorial Review Panel
Clinical Trial Research Analyst
ClinicalTrials.gov · FDA registry · trial protocol review
Medical Content Editor
PubMed literature · eligibility criteria · patient safety
Data Accuracy Reviewer
Phase classification · enrollment status · sponsor verification
⚕️ Medical Disclaimer: ClinicalMetric provides research intelligence only. Always consult a qualified healthcare provider before making clinical decisions or participating in a trial.
Publisher
ClinicalMetric
Independent Clinical Trial Intelligence
Tracks 400,000+ active clinical trials worldwide. Updated daily from ClinicalTrials.gov (NIH/NLM), FDA IND registry, and EudraCT (EU Clinical Trials Register).
Research Methodology
Articles are researched from primary registry sources: ClinicalTrials.gov XML feeds, FDA trial databases, and peer-reviewed literature. Trial status, phase, enrollment, and eligibility data is sourced directly from registry APIs — not secondary aggregators.
Trial status, enrollment, and eligibility information changes frequently. ClinicalMetric syncs with ClinicalTrials.gov daily. Editorial articles are reviewed quarterly or when major protocol amendments are published. Always verify trial status directly on ClinicalTrials.gov before making clinical decisions.
Clinical Trial Research & Analysis · Last updated April 2026
Analysis compiled from ClinicalTrials.gov (NIH/NLM), FDA trial registry data, and peer-reviewed clinical research. ClinicalMetric tracks 400,000+ active clinical trials worldwide, updated daily from the ClinicalTrials.gov AACT database.
Get Weekly Clinical Trial Alerts
New recruiting trials from NIH, NCI, and 40+ sponsors — every Monday. Free forever.
✓ You're on the list!
◆ Clinical Trial Intelligence at a Glance
400K+
Active trials tracked
200+
Countries with active trials
4
Clinical trial phases
Daily
Data refresh from ClinicalTrials.gov
◆ Clinical Trial Phase Transition Success Rates
Phase 1 → Phase 2 success~63%
Phase 2 → Phase 3 success~32%
Phase 3 → Approval~58%
Overall FDA approval rate~12%
Source: Biotechnology Innovation Organization (BIO) Clinical Development Success Rates — approximate industry averages.
◆ Clinical Trial Development Timeline
Mo 1–6
Preclinical + IND Filing
Mo 6–18
Phase 1 (Safety)
Mo 18–48
Phase 2 (Efficacy)
Mo 48–84
Phase 3 (Pivotal)
Mo 84–96
FDA Review / NDA
Mo 96+
Approval + Phase 4
Timeline is approximate. Total development from preclinical to approval averages 6–13 years.
Our analysts monitor 400,000+ clinical trials daily across oncology, neurology, cardiology, and rare diseases. All data sourced from ClinicalTrials.gov and FDA.gov.
🔬 400K+ trials tracked🌍 200+ countries🔄 Updated: April 2026
◆ Common Questions About Clinical Trials
What is a clinical trial?
+
A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).
How do I find clinical trials I'm eligible for?
+
You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.
Are clinical trials safe to participate in?
+
Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.
What are the phases of clinical trials?
+
Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.
Do participants get paid for joining clinical trials?
+
Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology
We use cookies to analyze site traffic and improve your experience. By clicking "Accept", you consent to our use of cookies as described in our Privacy Policy.
◆ Free Clinical Trial Alerts
Get Weekly Clinical Trial Alerts
New recruiting trials from NIH, NCI, and 40+ sponsors — every Monday. Free.